ProQR Therapeutics
PRQR | NASDAQ
$1.18
-$0.23 (-16.31%)
At close: Nov 16, 2026, 4:00 PM ET
$1.23
+$0.05 (+4.24%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-16.31%
(1D)No price chart data available for 1D timeframe.
Rating
39.2
+4.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #549/1021 (Top 54%)
Key Statistics
Market Data
Market Cap $166.52M
1D Range
1.18 1.43
52W Range
1.18 2.45
Valuation (TTM)
PE -2.53
PB 1.84
EV/EBITDA -1.11
Valuation (NTM)
Forward PE N/A
Forward PEG 1.79
Price Target $3.00
Cash Flow
FCF Yield -33.2%
SBC Adj. FCF Yield -35.7%
SBC Impact -7.5%
Margins
Gross Margin 92.3%
Operating Margin -232.7%
FCF Margin -270.8%
Growth (CAGR)
Revenue 3Y | 5Y 66.3% |
95.3%
Dil EPS 3Y | 5Y -17.7% |
23.0%
FCF 3Y | 5Y -16.4% |
-18.6%
Returns
ROA -31.8%
ROE -68.4%
ROIC -41.9%
Financial Health
Net Cash
€112.58M ($128.58M)
Current Ratio 3.49
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes tw...
Sector Healthcare
Industry Biotechnology
Employees 166
IPO Date Sep 18, 2014
Website www.proqr.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.1
Beat +11.17%
YoY:
+15.03% REV
$5.84M
Beat +35.77%
YoY:
+71.04%Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$3.00
Upside
+154.24%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PRQR